Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 2/2024

25-01-2024 | Prostate Cancer

Impact of PSMA PET on Prostate Cancer Management

Authors: Adam B. Weiner, MD, Raag Agrawal, BS, Luca F. Valle, MD, Ida Sonni, MD, Amar U. Kishan, MD, Matthew B. Rettig, MD, Steven S. Raman, MD, Jeremie Calais, MD, MSc, Paul C. Boutros, PhD, MBA, Robert E. Reiter, MD, MBA

Published in: Current Treatment Options in Oncology | Issue 2/2024

Login to get access

Opinion statement

PSMA-PET has been a practice-changing imaging biomarker for the management of men with PCa. Research suggests improved accuracy over conventional imaging and other PET radiotracers in many contexts. With multiple approved PSMA-targeting radiotracers, PSMA PET will become even more available in clinical practice. Its increased use requires an understanding of the prospective data available and caution when extrapolating from prior trial data that utilized other imaging modalities. Future trials leveraging PSMA PET for treatment optimization and management decision-making will ultimately drive its clinical utility.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71:209–49.CrossRef
2.
Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927–35.PubMed
3.
Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53:227–30.PubMed
4.
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5.PubMed
5.
Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645–53.PubMedPubMedCentralCrossRef
6.
Eder M, Schäfer M, Bauder-Wüst U, Hull W-E, Wängler C, Mier W, Haberkorn U, Eisenhut M. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97.PubMedCrossRef
7.
Will L, Sonni I, Kopka K, Kratochwil C, Giesel FL, Haberkorn U. Radiolabeled prostate-specific membrane antigen small-molecule inhibitors. Q J Nucl Med Mol Imaging. 2017;61:168–80.PubMedCrossRef
8.
Calais J, Ceci F, Eiber M, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20:1286–94.PubMedPubMedCentralCrossRef
9.
Morigi JJ, Stricker PD, Van Leeuwen PJ, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185–90.PubMedCrossRef
10.
Fraser M, Koontz B, Emmenegger U, et al. What is oligometastatic prostate cancer? Eur Urol Focus. 2019;5:159–61.PubMedCrossRef
11.
•• Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6:650–9. Randomized study showing patients with PSMA PET–positive metastatic lesions that were not treated with radiotherapy had shorter progression-free survival.PubMedPubMedCentralCrossRef
12.
Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2018;45:12–9.PubMedCrossRef
13.
Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353–66.PubMedPubMedCentralCrossRef
14.
Ranasinghe W, Chapin BF, Kim IY, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU Int. 2020;125:792–800.PubMedCrossRef
15.
Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, Delaere KPJ, van Moorselaar RJA, Verhagen PCMS, van Andel G. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75:410–8.PubMedCrossRef
16.
Tang C, Sherry AD, Haymaker C, et al. Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 Randomized Clinical Trial. JAMA Oncol. 2023;9:825–34.PubMedCrossRef
17.
Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446–53.PubMedCrossRef
18.
19.
Emmett L, Buteau J, Papa N, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): A prospective multicentre study. Eur Urol. 2021;80:682–9.PubMedCrossRef
20.
• Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16. Randomized study showing PSMA PET for initial staging improved disease detection and altered management frequently.PubMedCrossRef
21.
22.
•• Hope TA, Eiber M, Armstrong WR, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021. https://​doi.​org/​10.​1001/​jamaoncol.​2021.​3771. Prospective study showing the accuracy of PSMA PET for detecting nodal disease at the time of surgery and formed the basis for FDA approval.CrossRefPubMedPubMedCentral
23.
• Pienta KJ, Gorin MA, Rowe SP, et al. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY). J Urol. 2021;206:52–61. Prospective trial evaluating the accuracy of 18F-DCFPyL for both primary staging and biochemical recurrence.PubMedPubMedCentralCrossRef
24.
• Surasi DS, Eiber M, Maurer T, et al. Diagnostic performance and safety of positron emission tomography with 18F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE). Eur Urol. 2023;84:361–70. Prospective trial evaluating the accuracy of 18F-rhPSMA-7.3 for primary staging patients with unfavorable intermediate to very high risk PCa.PubMedCrossRef
25.
Chow KM, So WZ, Lee HJ, et al. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: a systematic review and meta-analysis. Eur Urol. 2023;84:36–48.PubMedCrossRef
26.
Sonni I, Felker ER, Lenis AT, et al. Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and mpMRI with a histopathology gold standard in the detection, intraprostatic localization, and determination of local extension of primary prostate cancer: results from a prospective single-center imaging trial. J Nucl Med. 2022;63:847–54.PubMedPubMedCentralCrossRef
27.
Berger I, Annabattula C, Lewis J, et al. 68Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology. Prostate Cancer Prostatic Dis. 2018;21:204–11.PubMedCrossRef
28.
Schaeffer EM, Srinivas S, Adra N, et al. NCCN Guidelines® Insights: prostate cancer, Version 1.2023. J Natl Compr Canc Netw. 2022;20:1288–98.PubMed
29.
Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243–62.PubMedCrossRef
30.
• Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5:856–63. First large prospective trial establishing the abilities of 68Ga-PSMA-11 PET for localizing recurrence following primary treatment.PubMedPubMedCentralCrossRef
31.
• Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27:3674–82. Randomized study which characterized the ability of PSMA PET to localize recurrences after primary treatment.PubMedPubMedCentralCrossRef
32.
• Jani AB, Ravizzini GC, Gartrell BA, et al. Diagnostic performance and safety of 18F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT). J Urol. 2023;210:299–311. Prospective trial evaluating the accuracy of 18F-rhPSMA-7.3 for detecting recurrences in patients following primary treatment.PubMedCrossRef
33.
Pozdnyakov A, Kulanthaivelu R, Bauman G, Ortega C, Veit-Haibach P, Metser U. The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023;26:240–8.PubMedCrossRef
34.
Emmett L, Van Leeuwen PJ, Nandurkar R, et al. Treatment outcomes from 68Ga-PSMA PET/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: Prognostic value of a negative PSMA PET. J Nucl Med. 2017;58:1972–6.PubMedCrossRef
35.
Zamboglou C, Peeken JC, Janbain A, et al. Development and validation of a multi-institutional nomogram of outcomes for PSMA-PET–based salvage radiotherapy for recurrent prostate cancer. JAMA Netw Open. 2023;6:e2314748.PubMedPubMedCentralCrossRef
36.
Calais J, Czernin J, Cao M, et al. 68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med. 2018;59:230–7.PubMedPubMedCentralCrossRef
37.
Calais J, Armstrong WR, Kishan AU, Booker KM, Hope TA, Fendler WP, Elashoff D, Nickols NG, Czernin J. Update from PSMA-SRT trial NCT03582774: a randomized phase 3 imaging trial of prostate-specific membrane antigen positron emission tomography for salvage radiation therapy for prostate cancer recurrence powered for clinical outcome. Eur Urol Focus. 2021;7:238–40.PubMedCrossRef
38.
Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14:15–25.PubMedCrossRef
39.
40.
Glicksman RM, Metser U, Vines D, et al. Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: a prospective phase II trial testing the oligometastasis hypothesis [formula presented]. Eur Urol. 2021;80:374–82.PubMedCrossRef
41.
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New Engl J Med. 2015;373:737–46.PubMedCrossRef
42.
Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65:1058–66.PubMedCrossRef
43.
Dai B, Zhang S, Wan F-N, et al. Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial. Eur Urol Oncol. 2022;5:519–25.PubMedCrossRef
44.
Rajwa P, Zattoni F, Maggi M, et al. Cytoreductive radical prostatectomy for metastatic hormone-sensitive prostate cancer-evidence from recent prospective reports. Eur Urol Focus. 2023;9:637–41.PubMedCrossRef
45.
Bossi A, Foulon S, Maldonado X, et al. Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): results of PEACE-1, a phase 3 randomized trial with a 2x2 design. JCO. 2023;41:LBA5000–LBA5000.CrossRef
46.
Deek MP, Van der Eecken K, Sutera P, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol. 2022;40:3377–82.PubMedPubMedCentralCrossRef
47.
48.
Ma TM, Czernin J, Felix C, et al. LUNAR: a randomized phase 2 study of 177 lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol). BJU Int. 2023;132:65–74.PubMedCrossRef
49.
Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022;399:1695–707.PubMedCrossRef
50.
51.
Aggarwal RR, Heller G, Hillman DW, et al. Baseline characteristics associated with PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19). JCO. 2023;41:208–208.CrossRef
52.
53.
Ferdinandus J, Fendler WP, Farolfi A, et al. PSMA PET validates higher rates of metastatic disease for European Association of Urology biochemical recurrence risk groups: an international multicenter study. J Nucl Med. 2022;63:76–80.PubMedPubMedCentralCrossRef
54.
Jani AB, Schreibmann E, Goyal S, et al. 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet. 2021;397:1895–904.PubMedPubMedCentralCrossRef
55.
Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. New Engl J Med. 2020;383:1040–9.PubMedCrossRef
56.
Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. New Engl J Med. 2020;382:2197–206.PubMedCrossRef
57.
Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. New Engl J Med. 2018;378:1408–18.PubMedCrossRef
58.
Fendler WP, Weber M, Iravani A, et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res. 2019;25:7448–54.PubMedCrossRef
59.
Wang B, Liu C, Wei Y, et al. A prospective trial of 68Ga-PSMA and 18F-FDG PET/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration. Clin Cancer Res. 2020;26:4551–8.PubMedCrossRef
60.
Ali A, Hoyle A, Haran ÁM, et al. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2021;7:555–63.PubMedPubMedCentralCrossRef
61.
Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402–18.PubMedPubMedCentralCrossRef
62.
• Gafita A, Rauscher I, Weber M, et al. Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): An International Multicenter Study. J Nucl Med. 2022;63:1651–8. Retrospective study establishing a framework for disease treatment response based on PSMA PET imaging.PubMedPubMedCentral
63.
Gafita A, Rauscher I, Fendler WP, et al. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging. 2022;49:4271–81.PubMedCrossRef
64.
Gafita A, Djaileb L, Rauscher I, et al. Response evaluation criteria in PSMA PET/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer. Radiology. 2023;308:e222148.PubMedCrossRef
65.
Denis CS, Cousin F, Laere BD, Hustinx R, Sautois BR, Withofs N. Using 68Ga-PSMA-11 PET/CT for Therapy response assessment in patients with metastatic castration-resistant prostate cancer: application of EAU/EANM recommendations in clinical practice. J Nucl Med. 2022;63:1815–21.PubMedPubMedCentralCrossRef
66.
Murthy V, Gafita A, Thin P, Nguyen K, Grogan T, Shen J, Drakaki A, Rettig M, Czernin J, Calais J. Prognostic value of end-of-treatment PSMA PET/CT in patients treated with 177Lu-PSMA radioligand therapy: a retrospective, single-center analysis. J Nucl Med. 2023;64:1737–43.PubMedCrossRef
67.
Emmett L, John N, Pathmanandavel S, et al. Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). Ther Adv Med Oncol. 2023;15:17588359231156392.PubMedPubMedCentralCrossRef
68.
•• Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–103. Randomized study which showed PSMA-based radioligand therapy prolonged overall survival for advanced PCa.PubMedPubMedCentralCrossRef
69.
Fallah J, Agrawal S, Gittleman H, et al. FDA Approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2023;29:1651–7.PubMedPubMedCentralCrossRef
70.
Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804.PubMedCrossRef
71.
Hofman MS, Violet J, Hicks RJ, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33.PubMedCrossRef
72.
Hotta M, Gafita A, Czernin J, Calais J. Outcome of patients with PSMA PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis. J Nucl Med. 2022;63:1484–8.PubMedCrossRef
73.
Kuo PH, Yoo DC, Avery R, et al. A VISION substudy of reader agreement on 68Ga-PSMA-11 PET/CT scan interpretation to determine patient eligibility for 177Lu-PSMA-617 radioligand therapy. J Nucl Med. 2023;64:1259–65.PubMedPubMedCentralCrossRef
74.
Thang SP, Violet J, Sandhu S, et al. Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu-labelled PSMA radioligand therapy. Eur Urol Oncol. 2019;2:670–6.PubMedCrossRef
75.
• Gafita A, Calais J, Grogan TR, et al. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22:1115–25.  Retrospective study establishing a nomogram for predicting response to PSMA-based radioligand therapy.PubMedCrossRef
76.
Current K, Meyer C, Magyar CE, et al. Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intratumoral PSMA heterogeneity. Clin Cancer Res. 2020;26:2946–55.PubMedPubMedCentralCrossRef
77.
Gafita A, Marcus C, Kostos L, Schuster DM, Calais J, Hofman MS. Predictors and real-world use of prostate-specific radioligand therapy: PSMA and beyond. Am Soc Clin Oncol Educ Book. 2022;42:1–17.PubMed
78.
Hotta M, Gafita A, Murthy V, et al. PSMA PET tumor-to-salivary gland ratio to predict response to [177Lu]PSMA radioligand therapy: an international multicenter retrospective study. J Nucl Med. 2023;64:1024–9.PubMedCrossRef
79.
Seifert R, Seitzer K, Herrmann K, Kessel K, Schäfers M, Kleesiek J, Weckesser M, Boegemann M, Rahbar K. Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy. Theranostics. 2020;10:7812–20.PubMedPubMedCentralCrossRef
80.
81.
Caromile LA, Dortche K, Rahman MM, Grant CL, Stoddard C, Ferrer FA, Shapiro LH. PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer. Sci Signal. 2017;10:eaag3326.PubMedPubMedCentralCrossRef
82.
Pepe P, Pennisi M. Targeted biopsy in men high risk for prostate cancer: 68Ga-PSMA PET/CT Versus mpMRI. Clin Genitourin Cancer. 2023;S1558–7673(23):00146–55.
Metadata
Title
Impact of PSMA PET on Prostate Cancer Management
Authors
Adam B. Weiner, MD
Raag Agrawal, BS
Luca F. Valle, MD
Ida Sonni, MD
Amar U. Kishan, MD
Matthew B. Rettig, MD
Steven S. Raman, MD
Jeremie Calais, MD, MSc
Paul C. Boutros, PhD, MBA
Robert E. Reiter, MD, MBA
Publication date
25-01-2024
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 2/2024
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-024-01181-9

Other articles of this Issue 2/2024

Current Treatment Options in Oncology 2/2024 Go to the issue

ReviewPaper

Treating rare malignancies of the urinary tract — one size fits some

ReviewPaper

Desmoid Tumors: Current Perspective and Treatment

ReviewPaper

Research Progress on the Use of Metformin in Leukemia Treatment

ReviewPaper

Evaluation of Homologous Recombination Deficiency in Ovarian Cancer

ReviewPaper

A Comprehensive Review on the Role of Lurbinectedin in Soft Tissue Sarcomas

ReviewPaper

Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits